FDA Clears Eko’s Heart Disease Detection Ai For Adults And Pediatrics
AKLAND, Calif., July 12, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Eko Murmur Analysis Software (EMAS) for detecting and characterizing murmurs found in adults and pediatric patients. The next generation of Eko’s murmur detection capabilities grants Eko the first and only smart stethoscope on the market that can identify and differentiate, between innocent and structural, heart murmurs indicative of valvular heart disease.
Valvular heart disease is a life-threatening condition diagnosed in more than 8 million Americans1 and is often first identified with a stethoscope. While early detection is critical, millions of patients are expected to be undiagnosed, with as much as 57% of clinically significant valvular heart disease missed.2 By combining murmur analysis AI with its digital stethoscopes, Eko has transformed the traditional stethoscope into an objective, low-cost, and scalable screening tool that can identify significant structural heart disease in seconds on the front lines of care.
“This latest FDA clearance is another way in which Eko is improving access to better heart health through clinically-validated algorithms and best-in-class medical devices,” said Connor Landgraf, Co-founder & CEO of Eko. “By making heart disease screening algorithms and digital stethoscopes accessible in exam rooms around the country, we are moving towards a future in which more objective and consistent valvular heart disease screening can become the standard of care.”
The EMAS algorithm greatly improves the performance of healthcare professionals to accurately and consistently identify valvular heart disease, with an overall sensitivity of 85.6% and specificity of 84.4%.3 Further analysis showed that among adults 18 years and older, the EMAS algorithm identified structural murmurs with a sensitivity of 90.2% and specificity of 90.6%.4 When using traditional stethoscopes to detect significant valvular heart disease, general practitioners (GPs) were found to have a sensitivity of 44% and specificity of 69%.5
“Combining pathologic murmur detection with the stethoscope, a tool already deeply embedded in the practice of medicine, will allow for more accurate and efficient screening of heart valve disease in the community,” said Dr. Patrick McCarthy, Executive Director of the Bluhm Cardiovascular Institute at Northwestern Medicine. “Eko’s platform will help uncover early valvular heart disease in millions of people worldwide who may otherwise be missed, and make a significant impact on our ability to treat patients with life-saving interventions.”
Eko Murmur Analysis Software (EMAS) is a cloud-based machine learning algorithm that analyzes heart sounds, phonocardiogram and ECG signals (when available), captured using Eko’s smart stethoscopes. The software uses several methods to interpret the acquired signals, including signal processing and convolutional neural networks. The database used in the training and testing of EMAS is one of the world’s largest repositories of clinically validated heart sounds.
EMAS is FDA-cleared to automatically detect murmurs that may be present, and the murmur timing and character, including S1, S2, innocent heart murmurs, structural heart murmurs, and the absence of a heart murmur. The software is not intended as a sole means of diagnosis and is for use in environments where healthcare is provided by clinicians. The interpretations of heart sounds offered by the software are meant only to provide decision support to the clinician, who may use the result in conjunction with their own evaluation and clinical judgment. EMAS is intended for use on pediatric and adult patients.
Healthcare institutions interested in learning how they can use Eko to detect valvular heart disease can visit ekohealth.com/vhd.
Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.
- Centers for Disease Control and Prevention, Heart Disease, www.cdc.gov/heartdisease/valvular_disease.htm
- d’Arcy JL, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study, European Heart Journal (2016) 37, 3515-3522. doi:10.1093/eurheartj/ehw229
- FDA 510(k) Summary, K213794
- Eko Murmur Analysis Software User Manual
- Gardezi SKM, et al. Cardiac auscultation poorly predicts the presence of valvular heart disease in asymptomatic primary care patients, Heart 2018;104:1832–1835. doi:10.1136/heartjnl-2018-313082
Source: https://www.pharmalive.com/fda-clears-ekos-heart-disease-detection-ai-for-adults-and-pediatrics/
